Nuclera
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
Nuclera
1000 Technology Park Dr, Suite B, Billerica, MA 01821
Patents
Microfluidic devices containing reversibly pinned droplet samples and methods
2025-07-29 • US-12370550-B2
View DetailsMethod for reagent-specific driving EWoD arrays in microfluidic systems
2024-12-31 • US-12179203-B2
View DetailsWhat We Do
Integrated benchtop system for cell-free protein synthesis, digital microfluidics, and software-driven automation to accelerate the design, screening, and purification of proteins, including membrane proteins.
Provision of rapid, high-throughput protein expression and purification services through contract research organizations utilizing automated benchtop systems.
Biologics
Diagnostics
Drugs
Key People
Chief Executive Officer and Co-founder
Chairman of the Board
Chief Financial Officer
Chief Commercial Officer
Associate Vice President, Marketing
News & Updates
Received Innovate UK grants supporting advanced platform development, including for fast protein prototyping and engineering biology.
Ranked among the fastest-growing startups in the UK and Ireland for 2024.
Certified for cybersecurity practices by the UK government standard.
Recognized as one of the UK's most exciting growth-stage technology companies by Tech Nation.
Created new headquarters at One Vision Park to support operational growth and the commercial launch of protein prototyping technology.
Secured $75 million to accelerate commercial rollout of benchtop protein screening and production technology.
Received major UKRI grant, advancing AI-powered drug discovery using miniaturized protein screening and DNA-encoded library integration.
Announcement of collaboration to integrate rapid protein production and characterization workflows, reducing time from expression to analysis.
Expanded distribution network and support infrastructure in Asia-Pacific and Middle East markets.
Launch of a new workflow supporting production and stabilization of membrane proteins for drug discovery and structural biology.
Secured an additional $15.5M, bringing Series B funding to $58M, for the commercialization of the desktop protein bioprinter, enabling rapid and accessible protein production workflows.
Raised $42.5M to accelerate commercialization of benchtop protein printing technologies, supporting the launch of rapid protein prototyping platforms.
Featured at London Stock Exchange Group's Edison Open House event, showcasing innovation in automated protein production for life sciences.
Webinar featuring a rapid, scalable workflow for membrane protein expression using digital microfluidics, held on November 4, 2025.
Participation at PEGs Summit in Lisbon, Portugal, to showcase cell-free protein expression technologies.
Attendance at Drug Discovery World London to demonstrate protein expression workflow advances.